[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,948,602
  • Shares Outstanding, K 29,101
  • Annual Sales, $ 234,600 K
  • Annual Income, $ -13,230 K
  • EBIT $ 48 M
  • EBITDA $ 46 M
  • 60-Month Beta 0.79
  • Price/Sales 8.36
  • Price/Cash Flow N/A
  • Price/Book 50.12

Options Overview Details

View History
  • Implied Volatility 88.83% (+3.68%)
  • Historical Volatility 85.52%
  • IV Percentile 65%
  • IV Rank 28.76%
  • IV High 161.61% on 09/24/25
  • IV Low 59.45% on 12/22/25
  • Expected Move (DTE 7) 5.99 (8.65%)
  • Put/Call Vol Ratio 1.58
  • Today's Volume 31
  • Volume Avg (30-Day) 262
  • Put/Call OI Ratio 4.22
  • Today's Open Interest 5,537
  • Open Int (30-Day) 2,659
  • Expected Range 63.30 to 75.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 2
  • High Estimate $-0.08
  • Low Estimate $-0.55
  • Prior Year $-1.28
  • Growth Rate Est. (year over year) +75.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.07 +60.96%
on 04/09/26
72.36 -4.19%
on 05/05/26
+25.64 (+58.67%)
since 04/08/26
3-Month
31.23 +121.97%
on 02/11/26
72.36 -4.19%
on 05/05/26
+36.18 (+109.12%)
since 02/06/26
52-Week
11.40 +507.94%
on 09/16/25
72.36 -4.19%
on 05/05/26
+56.28 (+431.13%)
since 05/08/25

Most Recent Stories

More News
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for  Jemperli with GSK and imsidolimab with Vanda, today announced...

ANAB : 69.33 (+3.54%)
AnaptysBio's Royalty Cash Machine Looks Bulletproof but the Pipeline Spin-Off Creates New Questions

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 1, 2026 Current Price $66.76 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Cash Machine...

ANAB : 69.33 (+3.54%)
AnaptysBio's Royalty Cash Machine Looks Bulletproof but the Pipeline Spin-Off Creates New Questions

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 1, 2026 Current Price $66.76 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Cash Machine...

ANAB : 69.33 (+3.54%)
AnaptysBio's Royalty Cash Machine Looks Bulletproof but the Pipeline Spin-Off Creates New Questions

Barchart Research What to Expect from ANAB Earnings ANAB Generated May 1, 2026 Current Price $66.76 EPS Estimate $$-1.04 Consensus Rating Strong Buy Average Move 7.09% AnaptysBio's Royalty Cash Machine...

ANAB : 69.33 (+3.54%)
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

WASHINGTON , April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab...

ANAB : 69.33 (+3.54%)
VNDA : 6.28 (-1.72%)
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reduction Trial to adjudicate Anaptys’ contract claims and right to seek reversion of Jemperli against...

ANAB : 69.33 (+3.54%)
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

Focused on protecting and returning value of  Jemperli and imsidolimab royalties to shareholders Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately...

ANAB : 69.33 (+3.54%)
TRAX : 19.54 (+9.65%)
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

Anaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026 Anaptys to manage the financial collaborations for Jemperli with GSK and...

ANAB : 69.33 (+3.54%)
TRAX : 19.54 (+9.65%)
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-market Stockholders will receive one share of First Tracks Bio common stock for every one...

ANAB : 69.33 (+3.54%)
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

Inclusive of $80 million in proceeds from private placement by leading investors First Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026...

ANAB : 69.33 (+3.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 76.36
2nd Resistance Point 72.53
1st Resistance Point 69.74
Last Price 69.33
1st Support Level 63.12
2nd Support Level 59.29
3rd Support Level 56.50

See More

52-Week High 72.36
Last Price 69.33
Fibonacci 61.8% 49.07
Fibonacci 50% 41.88
Fibonacci 38.2% 34.69
52-Week Low 11.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.